Guinea Updates its Pharmaceutical Regulatory Law

The law gives authority to the National Directorate of Pharmacies and Medicines (DNPM) for medicines quality assurance and surveillance of medicines in circulation. A new system for regulating the national health commodity supply chain is also established. The revised legislation critically reinforces medicines governance in Guinea, where a significant number of pharmaceuticals on the national market are currently unregistered. The law stipulates that quality control is required for all health products in Guinea at all stages, including local production, registration for market authorization, importation, and post-marketing surveillance. This includes local production, registration for market authorization, importation, and post-marketing surveillance. The revision of the pharmaceutical regulatory law was facilitated by the Promoting the Quality of Medicines (PQM) program, which provided technical assistance for the revision of the country's pharmaceutical regulatory law. The PQM program also assisted the country's national quality control laboratory in meeting rigorous international standards for achieving ISO certification. The revision of the law was also supported by the Systems for Improved Access to Pharmaceuticals and Services (SIAPS) program. The new law has given Guinea a solid foundation for developing its pharmaceutical regulatory system. The law has the potential to replace substandard and falsified medicines in the national market with quality-assured medicines. The revision of the law is a critical step in strengthening the surveillance of medicines both at the time they are registered and once they enter the supply chain. This will help ensure that national authorities have the tools to combat falsified products and the proliferation of a parallel medicines market. The revision of the pharmaceutical regulatory law in Guinea is a significant step forward in the effort to improve health outcomes in the country. Guinea was considered ground zero of the Ebola epidemic and is at risk of malaria, making the quality of medicines a critical issue. The revised law will help to improve the quality of medicines in Guinea and reduce the risk of substandard and falsified medicines entering the market.